Physician profile
Blake Zelickson
NPI 1902292394
$4,074.55
in general payments reported to CMS, 2019-2025
23 companies · $991 in 2025
The $991 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.24 · 2021: $604 · 2022: $844 · 2023: $403 · 2024: $1,150 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,529 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,529.43 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $786.61 | 2021-2025 | Skyrizi |
| Lilly USA, LLC | $599.95 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $365.89 | 2022-2025 | |
| Ucb, INC. | $358.92 | 2021-2025 | Bimzelx |
| Janssen Biotech, INC. | $280.00 | 2021-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $255.86 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $253.93 | 2024-2025 | Dupixent, Libtayo |
| Incyte Corporation | $229.64 | 2021-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $171.00 | 2021-2025 | |
| Galderma Laboratories, L.P. | $138.45 | 2024-2025 | Nemluvio |
| Amgen INC. | $108.32 | 2024-2025 | Otezla, Otezla |
| Leo Pharma INC. | $92.40 | 2022-2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.97 | 2023-2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $68.38 | 2023-2025 | Zoryve |
| Allergan, INC. | $52.24 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $46.10 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $35.30 | 2021-2022 | |
| Merz North America, INC. | $34.55 | 2021-2022 | |
| Genentech USA, INC. | $32.19 | 2024 | Xolair |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.00 | 2019 | |
| Almirall LLC | $25.00 | 2024 | Klisyri |
| Revance Therapeutics, INC. | $22.15 | 2024 | Daxxify |
| Organon LLC | $10.70 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Zelickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.